Optogenetics

In plain language

Some single-celled algae have light-sensitive proteins that open tiny channels in the cell wall when light hits them. Scientists found that if the gene for one of these proteins is copied into nerve cells, those cells gain the same light sensitivity. Shining light of the right colour on them can make them fire, and a different light-sensitive protein can quieten them. Because the light can be switched on and off within a few thousandths of a second, researchers can control specific cells at precise times.

The human work so far has been in the eye. In retinitis pigmentosa, the light-sensing cells of the retina slowly die, but other cells in the retina can survive. In a 2021 case report, a patient who could not detect objects received an injection of a gene therapy into one eye and wore goggles that projected light onto the retina. With the goggles on, the patient could perceive, locate, count and touch objects. This was one patient and the vision was partial, so it is an early step, not a treatment available to most people.

Technical explanation

Optogenetics relies on microbial opsins, which are light-gated membrane proteins. Channelrhodopsin-2 (ChR2), a light-gated cation channel from the alga Chlamydomonas reinhardtii, depolarises a cell when it is illuminated with blue light. Boyden and colleagues (2005) reported that expressing ChR2 in mammalian neurons gave millisecond-timescale, genetically targeted optical control of neural activity. Light-driven pumps extend the toolkit in the other direction. Zhang and colleagues (2007) reported NpHR, a light-driven chloride pump from an archaeon, which can optically inhibit neural activity. Used together with ChR2, the two tools allowed bidirectional control of locomotion in C. elegans.

The main technical challenges are delivery and light access. Opsin genes are usually carried into target cells by viral vectors, and cell-type specificity depends on the promoter and the vector. Light must then reach the target cells. This is simple in cultured cells or thin tissue slices, but in intact animals and people it needs implanted fibres or light sources. The eye is the most accessible site, because light can reach the retina directly.

In the Nature Medicine case report, Sahel and colleagues (2021) injected a viral vector encoding the light-gated channel ChrimsonR into the eye of a patient with retinitis pigmentosa and used light-stimulating goggles. The authors describe it as the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy. The PIONEER trial (NCT03326336) is a Phase 1/2a, open-label, non-randomised, dose-escalation study of GS030 in retinitis pigmentosa. Its registered primary outcome is safety and tolerability at week 52.

What the evidence says

Each statement is typed by the strength of its evidence and linked to the source that supports it.

Limitations and open problems

• The only human efficacy evidence reviewed here is a single patient (Sahel and colleagues, 2021), and the published abstract does not state how long the patient was followed or report adverse events.
• The vision gained was partial. The reported abilities were perceiving, locating, counting and touching objects with the goggles on, not normal sight.
• Treatment needs both a gene therapy injected into the eye and wearable light-projecting goggles, so it is a combined product that the patient must use and maintain.
• The PIONEER trial is open-label and non-randomised, and its registered primary outcome is safety, so it cannot show benefit against a control group.
• Outside the retina, the sources reviewed here do not report human trials of optogenetics. Using light to reach deep brain tissue would need implanted light sources and further safety data on long-term expression of foreign proteins in human neurons.

Possible future uses

Timeline

1. Sept 2005Boyden and colleagues publish millisecond-timescale, genetically targeted optical control of neural activity in Nature Neuroscience. Sources: [1]
2. Apr 2007Zhang and colleagues publish multimodal fast optical interrogation of neural circuitry in Nature, adding the light-driven chloride pump NpHR for optical inhibition. Sources: [2]
3. 26 Sept 2018The PIONEER trial of GS030 in retinitis pigmentosa has a registered actual start date of 26 September 2018. Sources: [4]
4. 24 May 2021Nature Medicine publishes a case report of partial visual recovery in a blind patient after optogenetic therapy. The authors call it the first reported case of partial functional recovery in a neurodegenerative disease after optogenetic therapy. Sources: [3]
5. 5 Oct 2026The 2026 Nobel Prize in Physiology or Medicine is announced for optogenetics, shared by Karl Deisseroth, Peter Hegemann and Georg Nagel. Sources: [5]

Futures this could help bring about

How far away?

Restoring sight to blind people

Pilots · 4 of 8 steps done

Glossary

Opsin

A light-sensitive protein that changes the flow of ions across a cell membrane when it absorbs light.

Channelrhodopsin

A light-gated ion channel from algae. When it is placed in nerve cells, light can switch those cells on.

Adeno-associated virus (AAV)

A small virus, not known to cause disease, that is often used to carry genes into cells in gene therapy.

Retinitis pigmentosa

An inherited condition in which the light-sensing cells of the retina slowly degenerate, leading to progressive loss of vision.

Sources

1. peer reviewed paper
   Millisecond-timescale, genetically targeted optical control of neural activity
   Edward S. Boyden, Feng Zhang, Ernst Bamberg et al.. Nature Neuroscience, Sept 2005. DOI: 10.1038/nn1525. Accessed 21 Oct 2026.
2. peer reviewed paper
   Multimodal fast optical interrogation of neural circuitry
   Feng Zhang, Li-Ping Wang, Martin Brauner et al.. Nature, Apr 2007. DOI: 10.1038/nature05744. Accessed 21 Oct 2026.
3. peer reviewed paper
   Partial recovery of visual function in a blind patient after optogenetic therapy
   José-Alain Sahel, Elise Boulanger-Scemama, Chloé Pagot et al.. Nature Medicine, 24 May 2021. DOI: 10.1038/s41591-021-01351-4. Accessed 21 Oct 2026.
4. dataset
   Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa (NCT03326336)
   ClinicalTrials.gov, US National Library of Medicine, Mar 2026. Accessed 21 Oct 2026.
5. news
   Nobel medicine prize honours US and German scientists for optogenetics work
   Al Jazeera, 5 Oct 2026. Accessed 21 Oct 2026.

Revision history

3 changes since this profile was created.